YMAB Valuation

Y-mAbs Therapeutics Inc

Add to Watchlist

Advanced Chart

4.530

+0.06(1.342%)1D

Overview
Forecast
Valuation
Earnings

YMAB Relative Valuation

YMAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, YMAB is overvalued; if below, it's undervalued.

Historical Valuation

Y-mAbs Therapeutics Inc (YMAB) is now in the Fair zone, suggesting that its current forward PS ratio of 2.71 is considered Fairly compared with the five-year average of -14.05. The fair price of Y-mAbs Therapeutics Inc (YMAB) is between 2.53 to 26.15 according to relative valuation methord.

Relative Value

Fair Zone

2.53-26.15

Current Price：4.42

Fair

-4.33

Trailing

Forward

-3.36

EV/EBITDA

Y-mAbs Therapeutics Inc. (YMAB) has a current EV/EBITDA of -3.36. The 5-year average EV/EBITDA is -10.44. The thresholds are as follows: Strongly Undervalued below -25.48, Undervalued between -25.48 and -17.96, Fairly Valued between -2.93 and -17.96, Overvalued between -2.93 and 4.59, and Strongly Overvalued above 4.59. The current Forward EV/EBITDA of -3.36 falls within the Historic Trend Line -Fairly Valued range.

-2.93

EV/EBIT

Y-mAbs Therapeutics Inc. (YMAB) has a current EV/EBIT of -2.93. The 5-year average EV/EBIT is -9.63. The thresholds are as follows: Strongly Undervalued below -23.72, Undervalued between -23.72 and -16.68, Fairly Valued between -2.59 and -16.68, Overvalued between -2.59 and 4.46, and Strongly Overvalued above 4.46. The current Forward EV/EBIT of -2.93 falls within the Historic Trend Line -Fairly Valued range.

2.71

Y-mAbs Therapeutics Inc. (YMAB) has a current PS of 2.71. The 5-year average PS is 10.06. The thresholds are as follows: Strongly Undervalued below -8.03, Undervalued between -8.03 and 1.01, Fairly Valued between 19.11 and 1.01, Overvalued between 19.11 and 28.16, and Strongly Overvalued above 28.16. The current Forward PS of 2.71 falls within the Historic Trend Line -Fairly Valued range.

-6.06

P/OCF

Y-mAbs Therapeutics Inc. (YMAB) has a current P/OCF of -6.06. The 5-year average P/OCF is 139.68. The thresholds are as follows: Strongly Undervalued below -1217.38, Undervalued between -1217.38 and -538.85, Fairly Valued between 818.21 and -538.85, Overvalued between 818.21 and 1496.74, and Strongly Overvalued above 1496.74. The current Forward P/OCF of -6.06 falls within the Historic Trend Line -Fairly Valued range.

-5.30

P/FCF

Y-mAbs Therapeutics Inc. (YMAB) has a current P/FCF of -5.30. The 5-year average P/FCF is -13.49. The thresholds are as follows: Strongly Undervalued below -32.26, Undervalued between -32.26 and -22.88, Fairly Valued between -4.11 and -22.88, Overvalued between -4.11 and 5.27, and Strongly Overvalued above 5.27. The current Forward P/FCF of -5.30 falls within the Historic Trend Line -Fairly Valued range.

Y-mAbs Therapeutics Inc (YMAB) has a current Price-to-Book (P/B) ratio of 2.42. Compared to its 3-year average P/B ratio of 3.82 , the current P/B ratio is approximately -36.54% higher. Relative to its 5-year average P/B ratio of 5.44, the current P/B ratio is about -55.42% higher. Y-mAbs Therapeutics Inc (YMAB) has a Forward Free Cash Flow (FCF) yield of approximately -8.56%. Compared to its 3-year average FCF yield of -14.97%, the current FCF yield is approximately -42.81% lower. Relative to its 5-year average FCF yield of -13.30% , the current FCF yield is about -35.60% lower.

2.42

P/B

Median3y

3.82

Median5y

5.44

-8.56

FCF Yield

Median3y

-14.97

Median5y

-13.30

Competitors Valuation Multiple

The average P/S ratio for YMAB's competitors is 3.23, providing a benchmark for relative valuation. Y-mAbs Therapeutics Inc Corp (YMAB) exhibits a P/S ratio of 2.71, which is -15.99% above the industry average. Given its robust revenue growth of 4.88%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

YMAB.O

Y-mAbs Therapeutics Inc

Eledon Pharmaceuticals Inc

RAPT Therapeutics Inc

Tiziana Life Sciences Ltd

Loss

278.66M

Performance Decomposition

Market capitalization of YMAB decreased by 68.76% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 19.93M to 20.90M.

The secondary factor is the Margin Expansion, contributed -25.26%to the performance.

Overall, the performance of YMAB in the past 1 year is driven by Revenue Growth. Which is more sustainable.

4.88%

19.93M → 20.90M

Revenue Growth

-25.26%

-33.26 → -24.86

Margin Expansion

-48.38%

-14.66 → -7.57

P/E Change

-68.76%